- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06235684
Clinnova-RD: um estudo de coorte prospectivo de pacientes com doenças reumatóides (Clinnova-RD)
Clinnova-RD: Um estudo de coorte prospectivo de pacientes com doenças reumatóides: um esforço transregional de saúde digital que revela o potencial da inteligência artificial e da ciência de dados nos cuidados de saúde
This study is part of the Clinnova program. This is a prospective cohort study including patients with RD recruited at the time of a treatment change. At least 800 participants (recruited in France, Germany and Luxembourg) will be enrolled, of which 100 participants are expected to be recruited in Luxembourg with the present study protocol. The mission of Clinnova is to support the digitalization of healthcare and precision medicine by creating a data-enabling environment for accessing, sharing and analyzing interoperable, high-quality health data. The main hypothesis is that treatment change decided by clinicians is predictable using objective surrogate markers derived from clinical, epidemiological, and omics data. Identifying these objective markers may facilitate future treatment decisions, provide new insights on the molecular causes for differential treatment response, pathogenesis and progression, and potential pointers for improved personalized therapeutic interventions.
Visão geral do estudo
Status
Condições
Descrição detalhada
Major unmet clinical needs in RD are participant stratification by the predicted response to different drugs and the stratification of participants by predicted disease course, which might result in more or less aggressive treatment approaches. In this context, key unmet needs that can be addressed by data science and artificial intelligence include:
- Identification of predictive biomarkers for drug response estimation and identification of prognostic biomarkers to estimate the future course of the disease, focusing on participants in whom treatment needs to be changed.
- Improved monitoring of participant well-being. During the first year, data related to demographics, lifestyle, laboratory and physical examinations will be collected at baseline, at month 3, at month 12 and in case of unscheduled visit. Questionnaires and standardised voice collection will be collected (optionally) at different time points using the Colive web app. Physical activity and sleep quality will be optionally monitored via a smartwatch that will be provided to interested participants. Biological sample(s) and imaging data will be collected at different time points (baseline; 3 months; 12 months; unscheduled visit). A long-term follow-up (starting from month 12 and up to 4 years after month 12) is foreseen in this study. During the long-term follow-up medical data are collected on a yearly basis, and questionnaires are collected every 6 months.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Jasmin Schulz, PhD
- Número de telefone: +35226970265
- E-mail: Jasmin.Schulz@lih.lu
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Either newly diagnosed with a RD requiring initiation of therapy OR treatment change at the time of inclusion
Descrição
Inclusion criteria:
● Signed informed consent form
-
≥ 18 years of age
-
Willing and able to comply with the protocol for the duration of the study including data and samples collection, study visits and examinations
-
Either newly diagnosed with a RD as defined in the diseases of interest below* requiring initiation of therapy OR treatment change , as per physician's discretion OR any increase in disease activity assessed by the rheumatologist to be relevant (e.g., flare(s) before the study visit) *For RA:
-
Participants fulfilling the 2010 ACR/EULAR criteria for RA
-
Newly diagnosed RA in the last 2 years requiring initiation/change of therapy OR any type of RA requiring treatment change
-
For SLE:
- Participants fulfilling the 2019 ACR/EULAR Classification Criteria of Systemic Lupus Erythematosus (SLE)
-
For SSc:
• Participants fulfilling the 2013 ACR/EULAR Classification Criteria for Systemic Sclerosis (Ssc)
-
For ASSD:
- Participants fulfilling the 2010 Connor's criteria for ASSD
-
Exclusion criteria
- Any condition that could potentially hamper the compliance with the study protocol, including study procedures and study visits (such as mental disability that makes it difficult or impossible to answer questionnaires)
- Not fluent in any of the following languages: French, English or German
- Known pregnancy Note: If the participant is pregnant after inclusion and/or follow-up, this is not a reason for withdrawal.
- Participation in a prospective randomised interventional trial
- Decrease of disease activity
- Treatment change due to the unavailability of medication
- Treatment change due to safety reasons
- Disease-specific exclusion criteria:
For RA:
• overlap of RA with any other rheumatic/immunologic disease
For SLE:
- overlap of SLE with any other rheumatic/immunologic disease
For SSc:
- overlap of SSc with any other rheumatic/immunologic disease
- other forms of SSc than diffuse cutaneous or limited cutaneous systemic sclerosis
For ASSD:
- overlap of ASSD with any other rheumatic/immunologic disease
- other forms of myositis
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
Single Arm study
Either newly diagnosed with a RD requiring initiation of therapy OR treatment change at the time of inclusion |
During the first year, data related to demographics, lifestyle, laboratory and physical examinations will be collected at baseline, at month 3, at month 12 and in case of unscheduled visit. Questionnaires and standardised voice collection will be collected (optionally) at different time points using the Colive web app. Physical activity and sleep quality will be optionally monitored via a smartwatch that will be provided to interested participants. Biological sample(s) and imaging data will be collected at different time points (baseline; 3 months; 12 months; unscheduled visit). A long-term follow-up (starting from month 12 and up to 4 years after month 12) is foreseen in this study. During the long-term follow-up medical data are collected on a yearly basis, and questionnaires are collected every 6 months.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
Identificar características clínicas, epidemiológicas e ômicas associadas à DR
Prazo: 2031
|
2031
|
Medidas de resultados secundários
Medida de resultado |
Prazo |
|---|---|
|
Estabelecer uma amostra e um banco de dados para permitir a pesquisa biomédica.
Prazo: 2031
|
2031
|
Outras medidas de resultado
Medida de resultado |
Prazo |
|---|---|
|
Desenvolver aplicações para uma melhor interação entre participantes e médicos, levando a melhores serviços de apoio à saúde.
Prazo: 2031
|
2031
|
Colaboradores e Investigadores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Outros números de identificação do estudo
- LUX-CLIN-002
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .